Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 51-58

  Guo, Wei ^a   Wei, Xiaoli ^a,b   Wu, Shuhong ^a   Wang, Li ^a   Peng, Henry ^a   Wang, Ji ^a   Fang, Bingliang ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

Antitumor; Flavonoids; JNK; NSC 741909; Reactive oxygen species

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 1[(4 CHLOROPHENYL)METHYL] 1H INDOLE 3 METHANOL; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; APIGENIN; FLAVONOID; GENISTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NSC 741909; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DRUG INTERACTIONS; ENZYME ACTIVATION; FLAVONOIDS; FOOD-DRUG INTERACTIONS; FREE RADICAL SCAVENGERS; HUMANS; INDOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; OSMOLAR CONCENTRATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES;

EID: 78049261467     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.08.057     Document Type: Article

References (42)

1. Badger A.M., Cook M.N., Lark M.W., Newman-Tarr T.M., Swift B.A., Nelson A.H., Barone F.C., Kumar S. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J. Immunol. 1998, 161:467-473.
2. Beecher G.R. Overview of dietary flavonoids: nomenclature, occurrence and intake. J. Nutr. 2003, 133:3248S-3254S.
3. Bernhard E.J., Stanbridge E.J., Gupta S., Gupta A.K., Soto D., Bakanauskas V.J., Cerniglia G.J., Muschel R.J., McKenna W.G. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res. 2000, 60:6597-6600.
4. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., Horner J.W., Cordon-Cardo C., Yancopoulos G.D., DePinho R.A. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
5. Cook S.J., Beltman J., Cadwallader K.A., McMahon M., McCormick F. Regulation of mitogen-activated protein kinase phosphatase-1 expression by extracellular signal-related kinase-dependent and Ca2+-dependent signal pathways in Rat-1 cells. J. Biol. Chem. 1997, 272:13309-13319.
6. Dai Y., Rahmani M., Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 2003, 22:7108-7122.
7. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103:239-252.
8. Deng Y., Ren X., Yang L., Lin Y., Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003, 115:61-70.
9. Deorukhkar A., Krishnan S., Sethi G., Aggarwal B.B. Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin. Investig. Drugs 2007, 16:1753-1773.
10. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
11. Dudley D.T., Pang L., Decker S.J., Bridges A.J., Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7686-7689.
12. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., Copeland R.A., Magolda R.L., Scherle P.A., Trzaskos J.M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 1998, 273:18623-18632.
13. Ficarra R., Tommasini S., Raneri D., Calabro M.L., Di Bella M.R., Rustichelli C., Gamberini M.C., Ficarra P. Study of flavonoids/beta-cyclodextrins inclusion complexes by NMR, FT-IR, DSC, X-ray investigation. J. Pharm. Biomed. Anal. 2002, 29:1005-1014.
14. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., Whitsett J.A., Koretsky A., Varmus H.E. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 2001, 15:3249-3262.
15. Guerrero S., Casanova I., Farre L., Mazo A., Capella G., Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000, 60:6750-6756.
16. Guo W., Wu S., Liu J., Fang B. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res. 2008, 68:7403-7408.
17. Guo W., Wu S., Wang L., Wang R.Y., Wei X., Liu J., Fang B. Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1). Mol. Cancer Ther. 2009, 8:441-448.
18. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410:1111-1116.
19. Kamata H., Honda S., Maeda S., Chang L., Hirata H., Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005, 120:649-661.
20. Kim S.K., Abdelmegeed M.A., Novak R.F. The mitogen-activated protein kinase kinase (mek) inhibitor PD98059 elevates primary cultured rat hepatocyte glutathione levels independent of inhibiting mek. Drug Metab. Dispos. 2006, 34:683-689.
21. Knebel A., Rahmsdorf H.J., Ullrich A., Herrlich P. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents. EMBO J. 1996, 15:5314-5325.
22. Leevers S.J., Paterson H.F., Marshall C.J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994, 369:411-414.
23. Liu J., Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res. 2005, 15:36-42.
24. Marais R., Light Y., Paterson H.F., Marshall C.J. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995, 14:3136-3145.
25. Merighi S., Benini A., Mirandola P., Gessi S., Varani K., Leung E., Maclennan S., Baraldi P.G., Borea P.A. Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor. Purinergic. Signal. 2006, 2:627-632.
26. Nemunaitis J., Cox J., Meyer W., Courtney A., Mues G. Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). Am. J. Clin. Oncol. 1997, 20:527-529.
27. Pacold M.E., Suire S., Perisic O., Lara-Gonzalez S., Davis C.T., Walker E.H., Hawkins P.T., Stephens L., Eccleston J.F., Williams R.L. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 2000, 103:931-943.
28. Panka D.J., Wang W., Atkins M.B., Mier J.W. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006, 66:1611-1619.
29. Pauwels B., Korst A.E., de Pooter C.M., Pattyn G.G., Lambrechts H.A., Baay M.F., Lardon F., Vermorken J.B. Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother. Pharmacol. 2003, 51:221-226.
30. Salh B.S., Martens J., Hundal R.S., Yoganathan N., Charest D., Mui A., Gomez-Munoz A. PD98059 attenuates hydrogen peroxide-induced cell death through inhibition of Jun N-Terminal Kinase in HT29 cells. Mol. Cell Biol. Res. Commun. 2000, 4:158-165.
31. Sato T., Koike L., Miyata Y., Hirata M., Mimaki Y., Sashida Y., Yano M., Ito A. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res. 2002, 62:1025-1029.
32. Schubbert S., Bollag G., Lyubynska N., Nguyen H., Kratz C.P., Zenker M., Niemeyer C.M., Molven A., Shannon K. Biochemical and functional characterization of germ line KRAS mutations. Mol. Cell. Biol. 2007, 27:7765-7770.
33. Shoba L.N., Newman M., Liu W., Lowe W.L. LY 294002, an inhibitor of phosphatidylinositol 3-kinase, inhibits GH-mediated expression of the IGF-I gene in rat hepatocytes. Endocrinology 2001, 142:3980-3986.
34. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
35. Tang F., Tang G., Xiang J., Dai Q., Rosner M.R., Lin A. The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol. Cell. Biol. 2002, 22:8571-8579.
36. Thimmaiah K.N., Easton J.B., Germain G.S., Morton C.L., Kamath S., Buolamwini J.K., Houghton P.J. Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J. Biol. Chem. 2005, 280:31924-31935.
37. Tournier C., Hess P., Yang D.D., Xu J., Turner T.K., Nimnual A., Bar-Sagi D., Jones S.N., Flavell R.A., Davis R.J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000, 288:870-874.
38. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
39. Wei H., Cai Q., Rahn R.O. Inhibition of UV light- and Fenton reaction-induced oxidative DNA damage by the soybean isoflavone genistein. Carcinogenesis 1996, 17:73-77.
40. Wei X., Guo W., Wu S., Wang L., Lu Y., Xu B., Liu J., Fang B. Inhibiting JNK dephosphorylation and induction of apoptosis by novel anticancer agent NSC-741909 in cancer cells. J. Biol. Chem. 2009, 284:16948-16955.
41. Weston C.R., Davis R.J. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 2002, 12:14-21.
42. Zheng C., Xiang J., Hunter T., Lin A. The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity. J. Biol. Chem. 1999, 274:28966-28971.